YiChang HEC ChangJiang Pharmaceutical Co Ltd 2018 SR
The report highlights Pharm HEC's 2018 performance, noting a 56.75% revenue increase and the inclusion of key products like Oseltamivir in the National Essential Drug List. The company focused on R&D, particularly in anti-virus and endocrine areas, and achieved breakthroughs in insulin product development. Environmental efforts included a 1.8 million kWh reduction in energy consumption through equipment upgrades and 100% standardized discharge of waste. Socially, the company emphasized employee safety with zero fatalities and engaged in community health initiatives like the China Influenza Forum.
Company: YiChang HEC ChangJiang Pharmaceutical Co Ltd
Sector: Health Care
Country: China
Year: 2018
Type: SR
Pages: 69
YiChang HEC ChangJiang Pharmaceutical Co Ltd
ESG Report
The report highlights Pharm HEC's 2018 performance, noting a 56.75% revenue increase and the inclusion of key products like Oseltamivir in the National Essential Drug List. The company focused on R&D, particularly in anti-virus and endocrine areas, and achieved breakthroughs in insulin product development. Environmental efforts included a 1.8 million kWh reduction in energy consumption through equipment upgrades and 100% standardized discharge of waste. Socially, the company emphasized employee safety with zero fatalities and engaged in community health initiatives like the China Influenza Forum.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Employees